{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T08:56:16Z","timestamp":1790758576748,"version":"4.1.0"},"reference-count":26,"publisher":"American Diabetes Association","issue":"6","content-domain":{"domain":["diabetesjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2013,6,1]]},"abstract":"\n OBJECTIVE<\/jats:title>\n The Treatment Options for type 2 Diabetes in Adolescents and Youth (TODAY) trial demonstrated that combination therapy with metformin plus rosiglitazone provided superior durability of glycemic control compared with metformin alone, with significantly lower treatment failure rates (38.6 vs. 51.7%), and metformin plus lifestyle was intermediate. Herein we describe the temporal changes in measures of \u03b2-cell function and insulin sensitivity over a 4-year period among the three treatments.<\/jats:p>\n <\/jats:sec>\n \n RESEARCH DESIGN AND METHODS<\/jats:title>\n TODAY participants (699) were tested periodically with an oral glucose tolerance test to determine insulin sensitivity (1\/fasting insulin [1\/IF]), insulinogenic index (\u25b3I30\/\u25b3G30) or C-peptide index (\u25b3C30\/\u25b3G30), and \u03b2-cell function relative to insulin sensitivity (oral disposition index [oDI]).<\/jats:p>\n <\/jats:sec>\n \n RESULTS<\/jats:title>\n During the first 6 months, metformin plus rosiglitazone exhibited a significantly greater improvement in insulin sensitivity and oDI versus metformin alone and versus metformin plus lifestyle; these improvements were sustained over 48 months of TODAY. Irrespective of treatment, those who failed to maintain glycemic control had significantly lower \u03b2-cell function (\u223c50%), higher fasting glucose concentration, and higher HbA1c at randomization compared with those who did not fail.<\/jats:p>\n <\/jats:sec>\n \n CONCLUSIONS<\/jats:title>\n The beneficial change in insulin sensitivity and the resultant lower burden on \u03b2-cell function achieved in the first 6 months with metformin plus rosiglitazone appear to be responsible for its superior glycemic durability over metformin alone and metformin plus lifestyle. However, initial \u03b2-cell reserve and HbA1c at randomization are independent predictors of glycemic durability. Therefore, efforts to preserve \u03b2-cell function before significant loss occurs and to reduce HbA1c may be beneficial in the treatment of youth with type 2 diabetes.<\/jats:p>\n <\/jats:sec>","DOI":"10.2337\/dc12-2393","type":"journal-article","created":{"date-parts":[[2013,5,23]],"date-time":"2013-05-23T20:01:58Z","timestamp":1369339318000},"page":"1749-1757","update-policy":"https:\/\/doi.org\/10.2337\/ada-journal-policies","source":"Crossref","is-referenced-by-count":278,"title":["Effects of Metformin, Metformin Plus Rosiglitazone, and Metformin Plus Lifestyle on Insulin Sensitivity and \u03b2-Cell Function in TODAY"],"prefix":"10.2337","volume":"36","author":[{"name":"TODAY Study Group","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1167","published-online":{"date-parts":[[2013,5,15]]},"reference":[{"key":"2022031222442644700_B1","doi-asserted-by":"crossref","first-page":"S177","DOI":"10.2337\/dc11-s215","article-title":"Treatment of type 2 diabetes in youth","volume":"34","author":"Flint","year":"2011","journal-title":"Diabetes Care"},{"key":"2022031222442644700_B2","doi-asserted-by":"crossref","first-page":"89","DOI":"10.2337\/diacare.25.1.89","article-title":"Effect of metformin in pediatric patients with type 2 diabetes: a randomized controlled trial","volume":"25","author":"Jones","year":"2002","journal-title":"Diabetes Care"},{"key":"2022031222442644700_B3","doi-asserted-by":"crossref","first-page":"2247","DOI":"10.1056\/NEJMoa1109333","article-title":"A clinical trial to maintain glycemic control in youth with type 2 diabetes","volume":"366","author":"Zeitler","year":"2012","journal-title":"N Engl J Med"},{"key":"2022031222442644700_B4","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1111\/j.1399-5448.2007.00237.x","article-title":"Treatment options for type 2 diabetes in adolescents and youth: a study of the comparative efficacy of metformin alone or in combination with rosiglitazone or lifestyle intervention in adolescents with type 2 diabetes","volume":"8","author":"Zeitler","year":"2007","journal-title":"Pediatr Diabetes"},{"key":"2022031222442644700_B5","doi-asserted-by":"crossref","first-page":"638","DOI":"10.2337\/diacare.28.3.638","article-title":"Youth type 2 diabetes: insulin resistance, beta-cell failure, or both?","volume":"28","author":"Gungor","year":"2005","journal-title":"Diabetes Care"},{"key":"2022031222442644700_B6","doi-asserted-by":"crossref","first-page":"100","DOI":"10.2337\/dc08-1030","article-title":"In vivo insulin sensitivity and secretion in obese youth: what are the differences between normal glucose tolerance, impaired glucose tolerance, and type 2 diabetes?","volume":"32","author":"Bacha","year":"2009","journal-title":"Diabetes Care"},{"key":"2022031222442644700_B7","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1111\/j.1399-5448.2009.00601.x","article-title":"Impaired \u03b2-cell sensitivity to glucose and maximal insulin secretory capacity in adolescents with type 2 diabetes","volume":"11","author":"Elder","year":"2010","journal-title":"Pediatr Diabetes"},{"key":"2022031222442644700_B8","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.2337\/diabetes.54.6.1735","article-title":"\u03b2-Cell function across the spectrum of glucose tolerance in obese youth","volume":"54","author":"Weiss","year":"2005","journal-title":"Diabetes"},{"key":"2022031222442644700_B9","doi-asserted-by":"crossref","first-page":"738","DOI":"10.2337\/db08-1372","article-title":"Phenotypic type 2 diabetes in obese youth: insulin sensitivity and secretion in islet cell antibody-negative versus -positive patients","volume":"58","author":"Tfayli","year":"2009","journal-title":"Diabetes"},{"key":"2022031222442644700_B10","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1016\/j.jpeds.2003.12.045","article-title":"Progressive beta cell failure in type 2 diabetes mellitus of youth","volume":"144","author":"Gungor","year":"2004","journal-title":"J Pediatr"},{"key":"2022031222442644700_B11","article-title":"Progressive deterioration of \u03b2-cell function in\u00a0obese youth with type 2 diabetes","author":"Bacha","journal-title":"Pediatr Diabetes"},{"key":"2022031222442644700_B12","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.2337\/db10-1392","article-title":"Effects of rosiglitazone, glyburide, and metformin on \u03b2-cell function and insulin sensitivity in ADOPT","volume":"60","author":"Kahn","year":"2011","journal-title":"Diabetes"},{"key":"2022031222442644700_B13","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1002\/(SICI)1096-9136(199804)15:4<297::AID-DIA572>3.0.CO;2-W","article-title":"UKPDS 26: sulphonylurea failure in non-insulin-dependent diabetic patients over six years","volume":"15","author":"Matthews","year":"1998","journal-title":"Diabet Med"},{"key":"2022031222442644700_B14","first-page":"4047","article-title":"Clinical review 135: the importance of beta-cell failure in the development and progression of type 2 diabetes","volume":"86","author":"Kahn","year":"2001","journal-title":"J Clin Endocrinol Metab"},{"key":"2022031222442644700_B15","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1111\/j.1399-5448.2011.00841.x","article-title":"Determinants of glycemic control in youth with type 2 diabetes at randomization in the TODAY study","volume":"13","author":"Bacha","year":"2012","journal-title":"Pediatr Diabetes"},{"key":"2022031222442644700_B16","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1111\/j.1399-5448.2011.00846.x","article-title":"Metformin monotherapy in youth with recent onset type 2 diabetes: experience from the prerandomization run-in phase of the TODAY study","volume":"13","author":"Laffel","year":"2012","journal-title":"Pediatr Diabetes"},{"key":"2022031222442644700_B17","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1210\/jc.2010-1642","article-title":"Characteristics of adolescents and youth with recent-onset type 2 diabetes: the TODAY cohort at baseline","volume":"96","author":"Copeland","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"key":"2022031222442644700_B18","doi-asserted-by":"crossref","first-page":"2136","DOI":"10.1210\/jc.2010-2813","article-title":"Surrogate estimates of insulin sensitivity in obese youth along the spectrum of glucose tolerance from normal to prediabetes to diabetes","volume":"96","author":"George","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"key":"2022031222442644700_B19","doi-asserted-by":"crossref","first-page":"2033","DOI":"10.2337\/dc11-0423","article-title":"Declining \u03b2-cell function relative to insulin sensitivity with escalating OGTT 2-h glucose concentrations in the nondiabetic through the diabetic range in overweight youth","volume":"34","author":"Burns","year":"2011","journal-title":"Diabetes Care"},{"key":"2022031222442644700_B20","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.jpeds.2011.12.050","article-title":"Oral disposition index in obese youth from normal to prediabetes to diabetes: relationship to clamp disposition index","volume":"161","author":"Sjaarda","year":"2012","journal-title":"J Pediatr"},{"key":"2022031222442644700_B21","doi-asserted-by":"crossref","first-page":"3014","DOI":"10.2337\/diabetes.51.10.3014","article-title":"Hyperinsulinemia in african-american children: decreased insulin clearance and increased insulin secretion and its relationship to insulin sensitivity","volume":"51","author":"Arslanian","year":"2002","journal-title":"Diabetes"},{"key":"2022031222442644700_B22","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/S0026-0495(97)90167-0","article-title":"Race and ethnicity determine serum insulin and C-peptide concentrations and hepatic insulin extraction and insulin clearance: comparative studies of three populations of West African ancestry and white Americans","volume":"46","author":"Osei","year":"1997","journal-title":"Metabolism"},{"key":"2022031222442644700_B23","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1111\/j.1399-543X.2005.00097.x","article-title":"Progression from normal glucose tolerance to type 2 diabetes in a young girl: longitudinal changes in insulin sensitivity and secretion assessed by the clamp technique and surrogate estimates","volume":"6","author":"Saad","year":"2005","journal-title":"Pediatr Diabetes"},{"key":"2022031222442644700_B24","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.jdiacomp.2012.09.011","article-title":"Impact of differences in glucose tolerance on the prevalence of a negative insulinogenic index","volume":"27","author":"Faulenbach","year":"2013","journal-title":"J Diabetes Complications"},{"key":"2022031222442644700_B25","doi-asserted-by":"crossref","first-page":"2427","DOI":"10.1056\/NEJMoa066224","article-title":"Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy","volume":"355","author":"Kahn","year":"2006","journal-title":"N Engl J Med"},{"key":"2022031222442644700_B26","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1056\/NEJMp078167","article-title":"The rosiglitazone story-lessons from an FDA Advisory Committee meeting","volume":"357","author":"Rosen","year":"2007","journal-title":"N Engl J Med"}],"container-title":["Diabetes Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/diabetesjournals.org\/care\/article-pdf\/36\/6\/1749\/615907\/1749.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/diabetesjournals.org\/care\/article-pdf\/36\/6\/1749\/615907\/1749.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,13]],"date-time":"2022-03-13T01:00:56Z","timestamp":1647133256000},"score":1,"resource":{"primary":{"URL":"https:\/\/diabetesjournals.org\/care\/article\/36\/6\/1749\/33280\/Effects-of-Metformin-Metformin-Plus-Rosiglitazone"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,5,15]]},"references-count":26,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2013,5,15]]},"published-print":{"date-parts":[[2013,6,1]]}},"URL":"https:\/\/doi.org\/10.2337\/dc12-2393","relation":{},"ISSN":["0149-5992","1935-5548"],"issn-type":[{"value":"0149-5992","type":"print"},{"value":"1935-5548","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,5,15]]}}}